Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Profit & Loss 
Valuation 
Analyst Note 
Balance Sheet 
Cash Flow 
Financial Ratio 
Qtr. Results 
News 
About
Zenotech Laboratories Ltd (532039)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532039 NSE: Pharmaceuticals & Drugs | Small Cap | Zenotech Labs. Share Price
₹44.29 -1.11 (-2.44%)
As on 24-Jul'26 16:59
Zenotech Laboratories Ltd (532039)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532039 NSE: Pharmaceuticals & Drugs | Small Cap | Zenotech Labs. Share Price
₹44.29 -1.11 (-2.44%)
As on 24-Jul'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹270 Cr.
Current Price
₹44.3
52-Week Low / High
₹34 / 63
TTM EPS
₹-0.2
TTM Sales
₹43.6 Cr.
Book Value per Share
₹15.6
P/E Ratio
0.00
Lower than its 5-year historical median
Industry PE
52.9
Price to Book (P/B)
2.84
Lower than its 5-year historical median
Price to Sales (P/S)
6.20
Lower than its 5-year historical median
EV/EBITDA
20.86
In line with its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-1.12%
Underperforms industry median
Return on Capital Employed (ROCE)
4.38%
Underperforms industry median
Return on Assets (ROA)
-0.98%
Operating Profit Margin
21.2%
Net Profit Margin
-2.46%
Gross Profit Margin
26.4%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
1.3%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-35.19%
Net Profit Growth (1 Year)
-
-119.07%
Asset Quality
Promoter Holding
68.84%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹34 Cr.
Equity
₹61 Cr.
Face Value
₹10
All Time Low / High
₹3.99 / 173.59
Check Before You Invest
Quality
Somewhat GoodValuation
Somewhat UndervaluedCheck Valuation charts
Price Trend
Weak
Is Zenotech Laboratories Ltd a good quality company?
Zenotech Laboratories Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Zenotech Laboratories Ltd performance compare with that of its Peers?
Revenue growth of Zenotech Laboratories Ltd vs industry peers?
Zenotech Laboratories Ltd revenue CAGR is 14.20%, compared to the industry median CAGR of 5.34%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Zenotech Laboratories Ltd?
Promoters hold 68.84% of the Zenotech Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Zenotech Laboratories Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 0.4% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Zenotech Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | -61.9% | -6% | 18.3% | 0.5% | 15.3% | 18.4% | 12.9% | 11.5% | 4.4% | - |
| Value Creation Index ⓘ | NA | -5.4 | -1.4 | 0.3 | -1.0 | 0.1 | 0.3 | -0.1 | -0.2 | -0.7 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 2.3 | 11.1 | 13 | 26 | 22.5 | 36.6 | 42.4 | 40.8 | 43.1 | 43.6 | 44 |
| Sales YoY Gr. | - | 395.1% | 17% | 99.7% | -13.7% | 62.9% | 16% | -3.8% | 5.4% | 1.3% | - |
| Adj EPS ⓘ | -5.8 | -1.9 | -0.5 | 1 | -0.2 | 3.6 | 1.9 | 1.4 | 0.7 | -0.1 | -0.2 |
| YoY Gr. | - | NA | NA | NA | -119.2% | NA | -47.9% | -28% | -48.5% | -120% | - |
| BVPS (₹) ⓘ | -18.2 | 6.9 | 6.4 | 8.1 | 7.9 | 11.6 | 13.5 | 14.8 | 15.8 | 15.6 | 15.6 |
| Adj Net Profit ⓘ | -21.1 | -11.8 | -3 | 6.3 | -1.2 | 22.2 | 11.6 | 8.3 | 4.3 | -0.9 | -1 |
| Cash Flow from Ops. ⓘ | 1.6 | -16.3 | -14 | 11.4 | 5.7 | 17.7 | 20.7 | 11.8 | 9.5 | 10.2 | - |
| Debt/CF from Ops. ⓘ | 33.2 | 0 | -1.4 | 1.6 | 3.6 | 0.3 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 39% | 14.2% | 0.9% | 1.3% | ||||
| Adj EPS ⓘ | NA | NA | -142% | -120% | ||||
| BVPSⓘ | NA | 14.5% | 5% | -1% | ||||
| Share Price | 0.4% | -3.1% | -7.7% | -28.3% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 37.7 | 99.2 | -7.5 | 14.3 | -2.5 | 37.3 | 15.1 | 9.6 | 4.6 | -0.9 | -1.2 |
| Op. Profit Mgn % ⓘ | -460.4 | -70.5 | -26 | 34.5 | 28.4 | 47.8 | 48.8 | 42.3 | 33 | 21.3 | 23.2 |
| Net Profit Mgn % ⓘ | -937.4 | -106.3 | -23.3 | 24.3 | -5.4 | 60.7 | 27.3 | 20.4 | 9.9 | -2 | -2.5 |
| Debt to Equity ⓘ | -0.8 | 0 | 0.5 | 0.4 | 0.4 | 0.1 | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 610 | 148 | 239 | 125 | 111 | 76 | 78 | 100 | 120 | 129 | 188 |
| Cash Conv. Cycle ⓘ | 106 | -70 | -42 | -44 | -9 | 9 | -6 | -10 | 17 | 39 | 131 |
Profit And Loss
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 11 | 13 | 26 | 22 | 37 | 42 | 41 | 43 | 44 |
| Operating Expenses ⓘ + | 13 | 19 | 17 | 17 | 16 | 19 | 22 | 24 | 29 | 34 |
| Operating Profit ⓘ | -10 | -8 | -4 | 9 | 6 | 17 | 21 | 17 | 14 | 9 |
| Operating Profit Margin (%) | -461.0% | -70.6% | -27.0% | 34.5% | 28.4% | 47.8% | 48.8% | 42.2% | 32.9% | 21.1% |
| Other Income ⓘ + | 0 | 2 | 5 | 1 | 0 | 1 | 1 | 1 | 2 | 2 |
| Interest ⓘ | 8 | 2 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 4 | 4 | 4 | 5 | 6 | 7 | 7 | 7 | 7 | 7 |
| Profit Before Tax ⓘ | -20 | -12 | -3 | 11 | -1 | 10 | 15 | 11 | 11 | 4 |
| Tax ⓘ | 0 | 0 | 0 | 0 | 0 | -12 | 3 | 3 | 5 | 5 |
| Profit After Tax | -20 | -12 | -3 | 11 | -1 | 22 | 12 | 8 | 6 | -1 |
| PAT Margin (%) | -881.0% | -106.0% | -24.0% | 41.4% | -5.4% | 60.7% | 27.3% | 20.3% | 13.0% | -2.5% |
| Adjusted EPS (₹) | -5.5 | -1.9 | -0.5 | 1.8 | -0.2 | 3.6 | 1.9 | 1.4 | 0.9 | -0.2 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Valuation of Zenotech Labs. - Standalone
Analyst's Notes
No data found!
Balance Sheet
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | -66 | 42 | 39 | 50 | 48 | 71 | 82 | 91 | 96 | 95 | |
| Debt + | 51 | 0 | 20 | 19 | 21 | 6 | 0 | 0 | 0 | 0 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 5 | 5 | 4 | 5 | 2 | 2 | 3 | 3 | 3 | 4 | |
| Others Liabilities ⓘ | 60 | 34 | 21 | 13 | 15 | 3 | 6 | 6 | 8 | 12 | |
| Total Liabilities ⓘ | 51 | 82 | 85 | 86 | 86 | 82 | 92 | 100 | 107 | 111 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 47 | 44 | 43 | 49 | 74 | 71 | 65 | 66 | 61 | 62 | |
| CWIP ⓘ | 0 | 2 | 17 | 29 | 2 | 0 | 5 | 2 | 4 | 4 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Inventories | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Trade Receivables | 0 | 0 | 2 | 2 | 4 | 4 | 3 | 3 | 7 | 9 | |
Cash Equivalents 
ⓘ
| 1 | 29 | 13 | 1 | 2 | 2 | 11 | 20 | 27 | 30 | |
| Others Assets ⓘ | 2 | 5 | 8 | 5 | 3 | 4 | 7 | 8 | 8 | 6 | |
| Total Assets ⓘ | 51 | 82 | 85 | 86 | 86 | 82 | 92 | 100 | 107 | 111 | |
Cash Flow
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 2 | -16 | -14 | 11 | 6 | 18 | 21 | 12 | 9 | 10 |
| Cash Flow From Investing Activity ⓘ + | -1 | -3 | -16 | -21 | -5 | -2 | -6 | -21 | 15 | -6 |
| Cash Flow From Financing Activity ⓘ + | -1 | 47 | 15 | -3 | 0 | -16 | -6 | 0 | 0 | 0 |
| Net Cash Flow ⓘ | 0 | 28 | -15 | -12 | 1 | -0 | 9 | -9 | 25 | 4 |
Financial Ratio
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | N/A | 0 | -7.73 | 24.35 | -2.48 | 37.26 | 15.15 | 9.6 | 6.01 | -1.12 |
| ROCE (%) | N/A | -61.88 | -5.95 | 18.32 | 0.48 | 15.26 | 18.39 | 12.89 | 11.46 | 4.38 |
| Asset Turnover Ratio | 0.04 | 0.17 | 0.16 | 0.31 | 0.26 | 0.44 | 0.49 | 0.43 | 0.42 | 0.4 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | 1 | N/A | 0.82 | 1.75 | 1.5 | 1.5 | N/A |
| Working Capital Days | ||||||||||
| Receivable Days | 28.20 | 0.10 | 33.10 | 29.60 | 46 | 38.60 | 31.20 | 29.40 | 45.40 | 67.90 |
| Inventory Days | 203.10 | 28.60 | 19.70 | 4.80 | 1.30 | 0.60 | 0 | 7.50 | 0 | 0 |
| Payable Days | 1,026.30 | 2,410 | 2,424 | 3,153.50 | 0 | 0 | 0 | 0 | 1,263.20 | 0 |
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Zenotech Laboratories Ltd FAQs
The current trading price of Zenotech Labs. on 24-Jul-2026 16:59 is ₹44.29.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Jul-2026 the market cap of Zenotech Labs. stood at ₹270.3 Cr
The latest P/E ratio of Zenotech Labs. as of 23-Jul-2026 is 0.00.
The latest P/B ratio of Zenotech Labs. as of 23-Jul-2026 is 2.84.
The 52-week high of Zenotech Labs. is ₹63.38 and the 52-week low is ₹33.55.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Zenotech Labs. is ₹43.61 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Zenotech Laboratories Ltd is a average quality company.
The key valuation ratios of Zenotech Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Zenotech Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Zenotech Laboratories Ltd
Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world.
The company aims to bring a constant pipeline of new biogeneric products to the market. The highly qualified and trained staff uses recombinant DNA technology and cGMP production methods to give the customers generic versions of biotherapeutic drugs comparable to the innovator product in quality, safety and efficacy.
Zenotech’s technical staff are well versed in gene cloning and expression, fermentation, downstream processing, protein purification, process validation and manufacture of recombinant DNA products from bacterial, yeast and mammalian cells.
Zenotech has a full fledged research and development facility for generating recombinant proteins for clinical development. The company plans to set up cGMP manufacturing facilities that will house multiple fermentors, bioreactors and chromatography systems to meet the demands of the Indian and other emerging markets.
Zenotech develops new biological entities in the areas of cancer and neurology. The company has initiated target identification and validation programs using gene and protein based technologies. This brings together proprietary technologies in the identification of cell surface proteins and receptors as candidate drug targets.
Zenotech utilizes validated targets for generating new therapeutic entites. The company plans to adopt a comprehensive approach to therapeutic monoclonal antibody generation by bringing together skills in the areas of recombinant DNA technology, protein purification and characterization in the development of new antigen and antibody-based therapeutics for clinical studies.
Zenotech offers comprehensive services for generating and characterizing recombinant proteins. The company provides a full range of services from cloning a gene, expression in microbial or mammalian systems, process development and generation of milligram to gram quantities of pure recombinant proteins. The company also offers functional, validated assays in both cell-based and cell-free formats for use in drug discovery.
Product range of the company includes:
Generics -- Biological
- Nugraf
- Macrogen
Chemical
- Gemcitabine for Injection
- Paclitaxel for Injection
- Docetaxel for Injection
- Irinotecan for Injection
- Oxaliplatin for Injection
- Epirubicin for Injection
- Bleomycin for Injection
- Cisplatin for Injection
- Carboplatin for Injection
- Ifosfamide for Injection
- Etoposide for Injection
New biologicals Zenotech develops new biological entities in the areas of
- Cancer
- Neurology
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
